Cargando…
A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase
BACKGROUND: For the majority of rare clinical missense variants, pathogenicity status cannot currently be classified. Classical homocystinuria, characterized by elevated homocysteine in plasma and urine, is caused by variants in the cystathionine beta-synthase (CBS) gene, most of which are rare. Wit...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993387/ https://www.ncbi.nlm.nih.gov/pubmed/32000841 http://dx.doi.org/10.1186/s13073-020-0711-1 |
_version_ | 1783493021959979008 |
---|---|
author | Sun, Song Weile, Jochen Verby, Marta Wu, Yingzhou Wang, Yang Cote, Atina G. Fotiadou, Iosifina Kitaygorodsky, Julia Vidal, Marc Rine, Jasper Ješina, Pavel Kožich, Viktor Roth, Frederick P. |
author_facet | Sun, Song Weile, Jochen Verby, Marta Wu, Yingzhou Wang, Yang Cote, Atina G. Fotiadou, Iosifina Kitaygorodsky, Julia Vidal, Marc Rine, Jasper Ješina, Pavel Kožich, Viktor Roth, Frederick P. |
author_sort | Sun, Song |
collection | PubMed |
description | BACKGROUND: For the majority of rare clinical missense variants, pathogenicity status cannot currently be classified. Classical homocystinuria, characterized by elevated homocysteine in plasma and urine, is caused by variants in the cystathionine beta-synthase (CBS) gene, most of which are rare. With early detection, existing therapies are highly effective. METHODS: Damaging CBS variants can be detected based on their failure to restore growth in yeast cells lacking the yeast ortholog CYS4. This assay has only been applied reactively, after first observing a variant in patients. Using saturation codon-mutagenesis, en masse growth selection, and sequencing, we generated a comprehensive, proactive map of CBS missense variant function. RESULTS: Our CBS variant effect map far exceeds the performance of computational predictors of disease variants. Map scores correlated strongly with both disease severity (Spearman’s ϱ = 0.9) and human clinical response to vitamin B(6) (ϱ = 0.93). CONCLUSIONS: We demonstrate that highly multiplexed cell-based assays can yield proactive maps of variant function and patient response to therapy, even for rare variants not previously seen in the clinic. |
format | Online Article Text |
id | pubmed-6993387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69933872020-02-04 A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase Sun, Song Weile, Jochen Verby, Marta Wu, Yingzhou Wang, Yang Cote, Atina G. Fotiadou, Iosifina Kitaygorodsky, Julia Vidal, Marc Rine, Jasper Ješina, Pavel Kožich, Viktor Roth, Frederick P. Genome Med Research BACKGROUND: For the majority of rare clinical missense variants, pathogenicity status cannot currently be classified. Classical homocystinuria, characterized by elevated homocysteine in plasma and urine, is caused by variants in the cystathionine beta-synthase (CBS) gene, most of which are rare. With early detection, existing therapies are highly effective. METHODS: Damaging CBS variants can be detected based on their failure to restore growth in yeast cells lacking the yeast ortholog CYS4. This assay has only been applied reactively, after first observing a variant in patients. Using saturation codon-mutagenesis, en masse growth selection, and sequencing, we generated a comprehensive, proactive map of CBS missense variant function. RESULTS: Our CBS variant effect map far exceeds the performance of computational predictors of disease variants. Map scores correlated strongly with both disease severity (Spearman’s ϱ = 0.9) and human clinical response to vitamin B(6) (ϱ = 0.93). CONCLUSIONS: We demonstrate that highly multiplexed cell-based assays can yield proactive maps of variant function and patient response to therapy, even for rare variants not previously seen in the clinic. BioMed Central 2020-01-30 /pmc/articles/PMC6993387/ /pubmed/32000841 http://dx.doi.org/10.1186/s13073-020-0711-1 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Sun, Song Weile, Jochen Verby, Marta Wu, Yingzhou Wang, Yang Cote, Atina G. Fotiadou, Iosifina Kitaygorodsky, Julia Vidal, Marc Rine, Jasper Ješina, Pavel Kožich, Viktor Roth, Frederick P. A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase |
title | A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase |
title_full | A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase |
title_fullStr | A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase |
title_full_unstemmed | A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase |
title_short | A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase |
title_sort | proactive genotype-to-patient-phenotype map for cystathionine beta-synthase |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993387/ https://www.ncbi.nlm.nih.gov/pubmed/32000841 http://dx.doi.org/10.1186/s13073-020-0711-1 |
work_keys_str_mv | AT sunsong aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT weilejochen aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT verbymarta aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT wuyingzhou aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT wangyang aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT coteatinag aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT fotiadouiosifina aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT kitaygorodskyjulia aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT vidalmarc aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT rinejasper aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT jesinapavel aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT kozichviktor aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT rothfrederickp aproactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT sunsong proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT weilejochen proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT verbymarta proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT wuyingzhou proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT wangyang proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT coteatinag proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT fotiadouiosifina proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT kitaygorodskyjulia proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT vidalmarc proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT rinejasper proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT jesinapavel proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT kozichviktor proactivegenotypetopatientphenotypemapforcystathioninebetasynthase AT rothfrederickp proactivegenotypetopatientphenotypemapforcystathioninebetasynthase |